rs141949212
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PM1PP3_ModeratePP5_Very_Strong
The NM_000275.3(OCA2):c.2339G>A(p.Gly780Asp) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000316 in 1,612,808 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 14/24 in silico tools predict a damaging outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000275.3 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
- oculocutaneous albinism type 2Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics, G2P, ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000275.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| OCA2 | NM_000275.3 | MANE Select | c.2339G>A | p.Gly780Asp | missense splice_region | Exon 23 of 24 | NP_000266.2 | ||
| OCA2 | NM_001300984.2 | c.2267G>A | p.Gly756Asp | missense splice_region | Exon 22 of 23 | NP_001287913.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| OCA2 | ENST00000354638.8 | TSL:1 MANE Select | c.2339G>A | p.Gly780Asp | missense splice_region | Exon 23 of 24 | ENSP00000346659.3 | ||
| OCA2 | ENST00000353809.9 | TSL:1 | c.2267G>A | p.Gly756Asp | missense splice_region | Exon 22 of 23 | ENSP00000261276.8 |
Frequencies
GnomAD3 genomes AF: 0.000184 AC: 28AN: 151992Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000398 AC: 10AN: 251398 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.0000157 AC: 23AN: 1460816Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 726866 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000184 AC: 28AN: 151992Hom.: 0 Cov.: 33 AF XY: 0.000108 AC XY: 8AN XY: 74228 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Tyrosinase-positive oculocutaneous albinism Pathogenic:6
PM2, PM3_Strong, PP3
The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.006%). Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.90; 3Cnet: 0.90). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000436090 /PMID: 28041643 /3billion dataset).A different missense change at the same codon (p.Gly780Ser) has been reported to be associated with OCA2 related disorder (PMID: 32741191). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline.
not provided Pathogenic:2
This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 780 of the OCA2 protein (p.Gly780Asp). This variant is present in population databases (rs141949212, gnomAD 0.06%). This missense change has been observed in individual(s) with clinical features of ocular albinism and/or oculocutaneous albinism (PMID: 28041643, 28976636, 29345414; internal data). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 436090). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. For these reasons, this variant has been classified as Pathogenic.
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28041643, 28976636, 32581362, 31589614, 34838614, 36098180, 38720644, 39201349, 29345414, 37650133, 38219857)
Oculocutaneous albinism Pathogenic:1
Variant summary: OCA2 c.2339G>A (p.Gly780Asp) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. Several computational tools predict a significant impact on normal splicing: Three predict the variant weakens the canonical 3' acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4e-05 in 251398 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in OCA2 causing Oculocutaneous Albinism (4e-05 vs 0.0043), allowing no conclusion about variant significance. c.2339G>A has been reported in the literature in multiple bi-allelic individuals affected with Oculocutaneous Albinism (example: Lasseaux_OCA2_PCMR_2018). These data indicate that the variant is very likely to be associated with disease. The following publication has been ascertained in the context of this evaluation (PMID: 29345414). Ten submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES Pathogenic:1
OCA2-related disorder Pathogenic:1
The OCA2 c.2339G>A variant is predicted to result in the amino acid substitution p.Gly780Asp. This variant has been reported in individuals with oculocutaneous albinism (Table S2, patient G004719, Carss et al. 2017. PubMed ID: 28041643; Marti et al. 2018. PubMed ID: 28976636; Table S3, Lasseaux et al. 2018. PubMed ID: 29345414). Additionally, at PreventionGenetics, we have identified this variant, along with a second pathogenic OCA2 variant in at least six unrelated patients with oculocutaneous albinism. This variant is reported in 0.060% of alleles in individuals of African descent in gnomAD, and has been classified as likely pathogenic and pathogenic by numerous labs in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/436090/). Given the evidence, we interpret c.2339G>A (p.Gly780Asp) as pathogenic.
Inborn genetic diseases Pathogenic:1
Albinism Pathogenic:1
Tyrosinase-positive oculocutaneous albinism;C1856895:SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES Pathogenic:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at